Axsome Therapeutics, Inc.

NASDAQ:AXSM

Biotechnology

Healthcare
$134.00 +0.10%

+$0.25 today

Market cap
$7.05B
Beta
0.60
P/E (TTM)
-68.6
EPS (TTM)
-$3.68
52W Low $96.09High $257.93

Volume 0.74M

Average 0.72M

AXSM Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Axsome Therapeutics, Inc.NASDAQ: AXSM

Net Receivables · Q2 FY2026 · quarter ended Jun 2026

Net receivables rises 39.5% from a year ago

Net receivables stood at $277.46M at the end of Q2 FY2026, up 39.5% from a year earlier and up 10.5% from the prior quarter. Over 3 fiscal years it compounded at +81.2% a year.

Context

  • Net receivables amounted to 36.4% of total assets at the end of Q2 FY2026, up 5.4 pp from a year earlier.
  • Net receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +39.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$277.46M+10.5% QoQ
Last fiscal yearDec 2025
$224.46M+58.1% YoY
Year agoJun 2025
$198.83M+39.5% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.5%——
1 year+58.1%——
3-year CAGR+81.2%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
224.46M USD
Year-over-year change
+58.1%

Net Receivables vs competitors

How AXSM compares with its peers on the latest reported figures

  • AXSM's Jun 2026 net receivables of $277.46M is the 3rd highest of the 11 companies compared; the peer median is $1.01M.
  • Its year-over-year change of +39.5% is the 3rd highest of 6, against a peer median of +31.5%.
  • Net receivables amounts to 36.4% of total assets for AXSM, versus a peer median of 0.2%.
AXSM Competitors Peer median
Net Receivables for AXSM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NBIXNeurocrine Biosciences, Inc.Sep 2026$957.3M +31.5%+25.2%17.0%
JAZZJazz Pharmaceuticals plcSep 2026$873.7M +14.3%+8.4%7.3%
AXSMAxsome Therapeutics, Inc.Jun 2026$277.46M +39.5%+81.2%36.4%
SUPNSupernus Pharmaceuticals, Inc.Jun 2026$211.66M +50.3%+4.3%14.8%
DNLIDenali Therapeutics Inc.Jun 2026$3.93M —-38.3%0.3%
XENEXenon Pharmaceuticals Inc.Sep 2026$1.17M +44.0%+11.6%0.1%
AVXLAnavex Life Sciences Corp.Dec 2025$844K -67.0%-36.7%0.6%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$58K ——0.0%
PRAXPraxis Precision Medicines, Inc.Sep 2026$0 ——0.0%
DFTXDefinium Therapeutics, Inc.Sep 2026$0 ——0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
Peer median (excluding AXSM) $1.01M+31.5%+6.4%0.2%

Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents86.47M200.84M386.19M315.35M322.93M
Short-term Investments00000
Net Receivables037.7M94.82M142M224.46M
Inventory04.32M15.14M15.73M27.94M
Other Current Assets02.78M8.12M11.98M13.65M
Total Current Assets86.52M245.64M504.26M485.06M588.99M
Property, Plant & Equipment (Net)944.01K1.14M7.62M5.97M20.86M
Goodwill010.31M12.04M12.04M12.04M
Intangible Assets059.66M53.29M46.89M40.52M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets322.91K14.72M11.03M18.53M27.4M
Total Non-current Assets1.27M85.83M83.97M83.43M100.82M
Total Assets87.79M331.48M588.24M568.5M689.81M
Account Payables13.15M38.61M40.68M72M65.54M
Short-term Debt000072.98M
Tax Payables000960K0
Deferred Revenue00000
Other Current Liabilities4.05M17.18M76.45M36.51M203.28M
Total Current Liabilities23.07M96.56M138.85M230.1M378.84M
Long-term Debt49.09M94.26M178.07M180.71M140.93M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities031.1M73.3M91.68M54.36M
Total Non-current Liabilities49.09M125.36M258.41M281.38M222.67M
Total Liabilities72.15M221.92M397.26M511.48M601.51M
Common Stock3.78K4K5K5K5K
Retained Earnings(409.2M)(596.33M)(835.57M)(1.12B)(1.31B)
Accumulated OCI00000
Other Stockholders Equity00(0)00
Minority Interest00000
Total Equity15.63M109.56M190.98M57.02M88.3M
Total Debt49.71M94.68M186.37M192.96M241.3M
Net Debt(36.76M)(106.16M)(199.82M)(122.4M)(81.64M)

Axsome Therapeutics, Inc.

NASDAQ:AXSM

Intrinsic Alpha fair value

Locked

Current Price

$134.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.